Sternfeld, M., Shoham, S., Klein, O., Flores-Flores, C., Evron, T., Idelson, G.H., Kitsberg, D., Patrick, J.W. and Soreq, H. (2000) Excess “read-through” acetylcholinesterase attenuates but the “synaptic” variant intensifies neurodeterioration correlates. Proceedings of the National Academy of Sciences of the United States of America, 97, 8647-8652.
http://dx.doi.org/10.1073/pnas.140004597

has been cited by the following article:

• TITLE: Evaluation of HemogloBindTM treatment for preparation of samples for cholinesterase analysis

  AUTHORS: Kevin G. McGarry, Ryan A. Bartlett, Nicholas J. Machesky, Thomas H. Snider, Robert A. Moyer, David T. Yeung, Matthew K. Brittain

  KEYWORDS: Acetylcholinesterase; Cholinesterase; HemogloBindTM; Sample Preparation; Hemoglobin

  JOURNAL NAME: Advances in Bioscience and Biotechnology, Vol.4 No.12, December 23, 2013

  ABSTRACT: Acetylcholine is an essential neurotransmitter found throughout the nervous system. Its action on postsynaptic receptors is regulated through hydrolysis by various carboxylesterases, especially cholinesterases (ChEs). The acute toxicity of organophosphate (OP) compounds is directly linked to their action as inhibitors of ChE. One widely used assay for evaluating ChE activity is a spectrophotometric method developed by Ellman et al. When the enzyme source is from tissues or, in particular, blood, hemoglobin displays a spectrophotometric peak at the same wave-length used to analyze cholinergic activity. This creates a substantial background that interferes with the Ellman’s assay and must be overcome in order to accurately monitor cholinesterase activity. Herein, we directly compare blood processing methods: classical method (1.67 ± 0.30 U/mL) and HemogloBindTM treatment (1.51 ± 0.17 U/mL), and clearly demonstrate that pretreatment of blood samples with HemoglobindTM is both a sufficient and rapid sample preparation method for the assessment of ChE activity using the Ellman’s method.